Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 248, Issue 6, 2010, Pages 785-791

  Di Lauro, Raffaello ^a   De Ruggiero, Pio ^a   Di Lauro, Raffaella ^a   Di Lauro, Maria Teresa ^a   Romano, Mario Rosario ^b,c  

^a CTO Hospital   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c UNIVERSITY OF MOLISE   (Italy)

Author keywords

Intravitreal bevacizumab; Proliferative diabetic retinopathy; Tractional retinal detachment

Indexed keywords

BEVACIZUMAB;

ARTICLE; CASE CONTROL STUDY; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC RETINOPATHY; DIATHERMY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EYE EXAMINATION; EYE FUNDUS; FOLLOW UP; HUMAN; IATROGENIC DISEASE; LASER COAGULATION; MAJOR CLINICAL STUDY; OPERATION DURATION; PEROPERATIVE CARE; PEROPERATIVE COMPLICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETINA TEAR; RETINOTOMY; TREATMENT DURATION; TREATMENT PLANNING; VITRECTOMY; VITREOUS HEMORRHAGE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; DIABETIC RETINOPATHY; ELECTROCOAGULATION; HUMANS; INJECTIONS; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITRECTOMY; VITREOUS BODY; VITREOUS HEMORRHAGE;

EID: 77952096101     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-010-1303-3     Document Type: Article

References (54)

1. A Avanta PV Algvere L Berglin S Seregard 1996 Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor Invest Ophthalmol Vis Sci 37 1929 1934
2. M Kliffen HS Sharma CM Mooy S Kerkvliet PT de Jong 1997 Increased expression of angiogenic growth factors in age-related maculopathy Br J Ophthalmol 81 154 162 10.1136/bjo.81.2.154 1:STN:280:DyaK2s3ht1eqtA%3D%3D 9059252
3. A Otani H Taxagi H Oh S Koyama Y Ogura M Matumura Y Honda 2002 Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes Microvasc Res 64 162 169 10.1006/mvre.2002.2407 1:CAS:528:DC%2BD38Xks1WmsbY%3D 12074642 (Pubitemid 34713242)
4. AP Adamis JW Miller MT Bernal DJ D'Amico J Folkman TK Yeo KT Yeo 1994 Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy Am J Ophthalmol 118 445 450 1:STN:280:DyaK2M%2FivFKmtQ%3D%3D 7943121
5. LP Aiello RL Avery PG Arrigg BA Keyt HD Jampel ST Shah LR Pasquale H Thieme MA Iwamoto JE Park, et al. 1994 Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders N Engl J Med 331 1480 1487 10.1056/NEJM199412013312203 1:STN:280: DyaK2M%2FlvFamsA%3D%3D 7526212 (Pubitemid 24356306)
6. MJ Tolentino JW Miller ES Gragoudas K Chatzistefanou N Ferrara AP Adamis 1996 Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in non humane primate Arch Ophthalmol 114 964 970 1:CAS:528:DyaK28XltFOitrg%3D 8694732 (Pubitemid 26271462)
7. RC Tripathi J Li BJ Tripathi KV Chalam AP Adamis 1998 Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma Ophthalmology 105 232 237 10.1016/S0161-6420(98)92782-8 1:STN:280:DyaK1c7jvFyiug%3D%3D 9479280 (Pubitemid 28090825)
8. K Lashkari T Hirose J Yazdany JW McMeel A Kazlauskas N Rahimi 2000 Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity Am J Pathol 156 1337 1334 1:CAS:528:DC%2BD3cXjtV2itro%3D 10751359
9. AP Adamis DT Shima 2005 The role of vascular endothelial growth factor in ocular health and disease Retina 25 111 118 10.1097/00006982-200502000-00001 15689799 (Pubitemid 40365933)
10. N Ferrara 2002 Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications Semin Oncol 29 10 14 1:CAS:528:DC%2BD3sXlvFSqsQ%3D%3D 12516033
11. LP Aiello EA Pierce ED Foley H Takagi H Chen L Riddle N Ferrara GL King LE Smith 1995 Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF- receptor chimeric proteins Proc Natl Acad Sci USA 92 10457 10461 10.1073/pnas.92.23.10457 1:CAS:528:DyaK2MXptlSjsbw%3D 7479819
12. Eyetech Study Group 2003 Antivascular endothelial growth factor therapy for subfoveal choroideal neovascularization secondary to age-related macular degeneration. Phase II study results Am J Ophthalmol 110 979 986
13. ES Gragoudas AP Adamis ET Cunningham Jr M Feinsod DR Guyer VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group 2004 Pegaptanib for neovascular age-related macular degeneration N Engl J Med 351 2805 2816 10.1056/NEJMoa042760 1:CAS:528:DC%2BD2MXhslyntw%3D%3D 15625332 (Pubitemid 40051904)
14. EW Ng DT Svima P Calias ET Cunningham Jr DR Guyer AP Adamis 2006 Pegaptanib, a targeted anti-VEGF optamer for ocular vascular disease Nat Rev Drug Discov 5 123 132 10.1038/nrd1955 1:CAS:528:DC%2BD28Xhslaqur8%3D 16518379
15. VEGF inhibition study in ocular neovascularization (V.I.S.I.O.N.) clinical trial group 2006 Pegaptanib sodium for neovascular age-related macular degeneration. two-years safety results of the two prospective, multicenter, controlled clinical trials Ophtalmology 113 992 1001 10.1016/j.ophtha.2006.02. 027 (Pubitemid 43795228)
16. VEGF inhibition study in ocular neovascularization (V.I.S.I.O.N.) clinical trial group 2006 Two-year efficacy results of the two randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration Ophthalmology 113 1508 1525
17. PJ Rosenfeld SD Schwartz MS Blumenkranz JW Miller JA Haller JD Reimann WL Greene N Shams 2005 Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration Ophthalmology 112 1048 1053 10.1016/j.ophtha.2005.01.043 15885778 (Pubitemid 40797460)
18. PJ Rosenfeld JS Hein G Hantsbarger N Shams 2006 Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration Ophthalmology 113 631 632 10.1016/j.ophtha. 2006.01.027
19. N Ferrara L D'amico N Shams M Lowman R Kim 2006 Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration Retina 26 859 870 10.1097/01.iae.0000242842.14624.e7 17031284 (Pubitemid 44547437)
20. JS Heier AN Antoszyk PR Pavak SR Leff PJ Rosenfeld TA Ciulla RF Dreyer RC Gentile JP Sy G Hantsbarger N Shams 2006 Ranibizumab for treatment of neovascular age-related macular degeneration Ophthalmology 113 633 642 10.1016/j.ophtha.2005.10.052 16483659
21. PJ Rosenfeld DM Brown JS Heier DS Boyer PK Kaiser CY Chung RY Kim MARINA Study Group 2006 Ranibizumab for neovascular age-related macular degeneration N Engl J Med 335 1419 1431 10.1056/NEJMoa054481 (Pubitemid 44511557)
22. DM Brown PK Kaiser M Michels G Soubrane JS Heier RY Kim JP Sy S Schneider ANCHOR Study Group 2006 Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 335 1432 1444 10.1056/NEJMoa062655 (Pubitemid 44511558)
23. N Ferrara KJ Millan HP Gerber W Novotny 2004 Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nature 3 391 400 10.1038/nrd1381 1:CAS:528:DC%2BD2cXktlCrt78%3D
24. J Marshall 2005 The role of bevacizumab as first-line therapy for colon cancer Semin Oncol 32 543 547 10.1053/j.seminoncol.2005.06.003 (Pubitemid 43080915)
25. PM Beer SJ Wong AM Hammad NS Falk MR O'Malley S Khan 2006 Vitreous level of unbound bevacizumab and unbound vascular endothelial growth factor in two patients Retina 26 871 876 10.1097/01.iae.0000233327.68433.02 17031285 (Pubitemid 44547438)
26. JS Shahar RL Avery G Heilweil A Barak E Zemel GP Lewis PT Johnson SK Fisher I Perlman A Loewenstein 2006 Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab Retina 26 262 269 10.1097/00006982-200603000-00002 16508424 (Pubitemid 44318177)
27. S Michels PJ Rosenfeld CA Puliafito EN Marcus AS Venkatraman 2005 Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label clinical study Ophthalmology 112 1035 1047 10.1016/j.ophtha.2005.02.007 15936441 (Pubitemid 40797459)
28. K Laud RF Spaide KB Freund J Slakter JM Klancnik Jr 2006 Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab Retina 26 960 963 10.1097/01.iae.0000240121.28034.c3 17031300 (Pubitemid 44547453)
29. A Tewari MS Dhalla RS Apte 2006 Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia Retina 26 1093 1094 10.1097/01.iae.0000254896.78766.74 17151505 (Pubitemid 44973239)
30. SD Nguyen S Sham S Tatlipinar DV Do EV Anden PA Campochiaro 2005 Bevacizumab suppresses choroidal neovascularization caused by pathological myopia Br J Ophthalmol 89 1368 1370 10.1136/bjo.2005.066431 1:STN:280: DC%2BD2Mvps1Ohtw%3D%3D 16170134 (Pubitemid 41638883)
31. RF Spaide YL Fisher 2006 Intravitreal bevacizumab (Avastin) treatment of proliferative retinopathy complicated by vitreous hemorrhage Retina 26 275 278 10.1097/00006982-200603000-00004 16508426 (Pubitemid 44318179)
32. R Jorge RA Costa D Calioli LP Cintra IU Scott 2006 Intravitreal bevacizumab (avastin) for persistent new vessels in diabetic retinopathy (IBEPE study) Retina 26 1006 1013 10.1097/01.iae.0000246884.76018.63 17151487 (Pubitemid 44973219)
33. JF Arevalo J Fromow-Guerra H Quiroz-Mercado JG Sanchez L Wu M Maia MH Berrocal A Solis-Vivanco ME Farah Pan-American Collaborative Retina Study Group 2007 Primary intravitreal bevacizumab (avastin) for diabetic macular oedema. results from the Pan-American Collaborative Retina Study Group at 6-month follow-up Ophthalmology 114 743 750 10.1016/j.ophtha.2006.12.028 17398322 (Pubitemid 46483714)
34. R di Lauro R di Lauro P de Ruggiero MT di Lauro A D'Aloia 2007 Bevacizumab (Avastin) preoperatorio nel trattamento chirurgico della retinopatia diabetica proliferante Notiziario Soc Oftalmol It 38 39 45
35. D Iturralde RF Spaide CB Meyerle JM Klancnik LA Yannuzzi YL Fisher J Sorenson JS Slakter KB Freund M Cooney HF Fine 2006 Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study Retina 26 279 284 10.1097/00006982-200603000-00005 16508427 (Pubitemid 44318180)
36. SA Pai R Shetty PB Vijayan G Venkatasubramaniam NK Yadav BK Shetty RB Babu KM Narayana 2007 Clinical, anatomic and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion Am J Ophthalmol 143 601 606 10.1016/j.ajo.2006.12.037 1:CAS:528: DC%2BD2sXjsVWitbw%3D 17306753 (Pubitemid 46452523)
37. MD Rabena DJ Pieramici AA Castellarin MA Nasir RL Avery 2007 Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion Retina 27 419 425 10.1097/IAE.0b013e318030e77e 17420692 (Pubitemid 46624280)
38. FM Davidorf JG Mouser RJ Derick 2006 Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection Retina 26 354 356 10.1097/00006982-200603000-00017 16508439 (Pubitemid 44318196)
39. ME Iliev D Domig U Wolf-Schnurrbursch U Wolf-Schnurrbursch S Wolf GM Sarra 2006 Bevacizumab (Avastin) in the treatment of neovascular glaucoma Am J Ophthalmol 142 1054 1056 10.1016/j.ajo.2006.06.066 1:CAS:528:DC%2BD28Xht12msLfM 17157590 (Pubitemid 44853889)
40. C Costagliola U Cipollone M Rinaldi M della Corte F Semeraro MR Romano 2008 Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma: a survey on 23 cases throughout 12-month follow-up Br J Clin Pharmacol 66 667 673 1:CAS:528:DC%2BD1cXhsVyntLfL 19032174
41. JO Mason MA Albert Jr R Vail 2006 Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema Retina 26 356 360 10.1097/00006982-200603000-00018 16508440 (Pubitemid 44318197)
42. H Quiroz-Mercado O Ustariz-Gonzales MA Martinez-Castellanos P Covarrubias F Dominguez V Sanchez-Huerta 2007 Our experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story Sem Ophthalmol 22 109 125 10.1080/08820530701420082 (Pubitemid 46918882)
43. A Travassos S Teixeira P Ferreira I Regadas AS Travassos FE Esperancinha I Prieto G Pires R van Velze A Valido C Machado Mdo 2007 Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity Ophthalmic Surg Lasers 38 233 237
44. J Yeoh C Williams P Allen R Buttery D Chiu B Clark R Essex M McCombe S Qureshi WG Campbell 2008 Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series Clin Experiment Ophthalmol 36 449 454 18942219
45. MR Romano SK Gibran J Marticorena D Wong H Heimann 2008 Can a preoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous haemorrhage? Eye 23 1698 1701 10.1038/eye.2008.354 19039332
46. S Rizzo F Genovesi-Ebert E Di Bartolo A Vento S Miniaci G Williams 2008 Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR) Graefes Arch Clin Exp Ophthalmol 246 837 842 10.1007/s00417-008-0774-y 1:CAS:528:DC%2BD1cXlsVGitLw%3D 18286296
47. RL Avery J Pearlman DJ Pieramici MD Rabena AA Castellarin MA Nasir MJ Giust R Wendel A Patel 2006 Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy Ophthalmology 113 1695 10.1016/j.ophtha.2006.05.064 17011951 (Pubitemid 44442453)
48. TU Krohne N Eter FG Holz CH Meyer 2008 Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans Am J Ophthalmol 146 508 512 10.1016/j.ajo.2008.05.036 1:CAS:528:DC%2BD1cXhtFektbfP 18635152
49. T Warner 1999 Relationships between the endothelin and nitric oxide pathways Clin Exp Pharmacol Physiol 26 247 252 10.1046/j.1440-1681.1999.03025.x 1:CAS:528:DyaK1MXhs12ru7o%3D 10081622 (Pubitemid 29128024)
50. PJ Rosenfeld AA Moshfeghi CA Puliafito 2005 Optical coherence tomography findings after intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration Ophthalmic Surg Lasers Imaging 36 331 335 16156152
51. RL Avery DJ Pieramici MD Rabena MD Rabena AA Castellarin MA Nasir MJ Giust R Wendel A Patel 2006 Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration Ophthalmology 113 363 372 10.1016/j.ophtha. 2005.11.019 16458968
52. RF Spaide K Laud MF Fine JM Klancnik Jr CB Meyerle LA Yannuzzi J Sorenson J Slakter YL Fisher MJ Cooney 2006 Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration Retina 26 383 390 10.1097/00006982-200604000-00001 16603955 (Pubitemid 44197628)
53. E Chen CH Park 2006 Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy Retina 26 699 700 10.1097/01.iae.0000225351.87205.69 16829817 (Pubitemid 44620378)
54. JF Arevalo M Maia HW Flynn Jr M Saravia RL Avery L Wu M Eid Farah DJ Pieramici MH Berrocal JG Sanchez 2008 Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy Br J Ophthalmol 92 213 216 10.1136/bjo.2007.127142 1:STN:280:DC%2BD1c%2FmvFWhsA%3D%3D 17965108 (Pubitemid 351224097)